Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNX-2100 Dose Finding Study for SARS-CoV-2 DTH Reactions
NCT05216510Phase 1Terminated
- Sponsor
- Tonix Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Sep 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of TNX-2100 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Tonix Pharmaceuticals. Primary endpoint: Assessment of Delayed-type Hypersensitivity Reactions (Maximal Area of Induration) at 96 hours. Started Jan 2022; status: terminated.
02
Drugs
TNX-2100
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05216510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05216510.